Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy

Almost all patients with multiple myeloma (MM) will eventually develop disease that has relapsed with or become refractory to available treatments and will require additional therapy. However, data are still lacking on how best to sequence regimens in the relapsed/refractory (RR) setting after the f...

Descripción completa

Detalles Bibliográficos
Autores principales: Raje, Noopur, Mateos, María-Victoria, Iida, Shinsuke, Reece, Donna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030780/
https://www.ncbi.nlm.nih.gov/pubmed/36944635
http://dx.doi.org/10.1038/s41408-023-00804-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030780/
https://www.ncbi.nlm.nih.gov/pubmed/36944635
http://dx.doi.org/10.1038/s41408-023-00804-y

Ejemplares similares